Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reference-Cited by-同舟云学术

Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Published:2021-08-12 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Dimeglio Chloé¹²,Herin Fabrice³,Da-Silva Isabelle¹,Jougla Isabelle³,Pradere Claire³,Porcheron Marion¹,Martin-Blondel Guillaume²⁴,Chapuy-Regaud Sabine¹,Izopet Jacques¹²

Affiliation:

1. CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse, France

2. INSERM UMR1291–CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France

3. Occupational Diseases Department, Toulouse University Hospital, Toulouse, France

4. Infectious and Tropical Diseases Department, Toulouse University Hospital, Toulouse, France

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab705/40830776/ciab705.pdf

Reference5 articles.

1. Are some COVID vaccines better than others? Interpreting and comparing esti;Rapaka;Clin Infect Dis,2021

2. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial;Borobia;Lancet,2021

3. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination;Barros-Martins;Nat Med,2021

4. Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France;Dimeglio;J Infect,2020

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes;Vaccine;2023-05

2. Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients;Frontiers in Immunology;2023-03-31

3. ‘Mix and Match’ vaccination: Is dengue next?;Vaccine;2022-10

4. Vaccination COVID-19 : technologies vaccinales, efficacité en vie réelle et spécificités;Médecine et Maladies Infectieuses Formation;2022-09

5. Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination;2022-08-24